More than 50 senior executives attend Deloitte Next Generation Therapies Global Roadshow in China

Deloitte Next Generation Therapies Global Roadshow in China kicked off on 28 October in Beijing and closed on 31 October in Shanghai. Under the theme Investments and Future Prospects of Cell & Gene Therapy (CGT), it explored how industry players can navigate the regulatory landscape to accelerate entry into China and achieve commercial excellence. The seminars brought together more than 50 senior executives from pharmaceutical, biotech, medical tech companies as well as life science focused VC/PE funds.

Deloitte China Northern Region Managing Partner Norman Sze and Eastern Region Managing Partner Dora Liu delivered the opening remarks at the Beijing and Shanghai seminars respectively. Jens Ewert, Deloitte China Life Sciences & Healthcare Industry Leader, also gave a welcoming speech. Deloitte China Life Sciences & Healthcare Financial Advisory Leader Jimmy Chan and Life Sciences & Healthcare Financial Advisory Partner Bob Chen chaired the Beijing and Shanghai sessions respectively.

Deloitte Global Life Sciences and Healthcare Financial Advisory Leader Philip Pfrang and US Life Sciences Consulting Managing Director Amit Agarwal shared global healthcare trends and an overview of the CGT market. They pointed out that CGTs alter the entire pharmaceutical ecosystem, representing the next technology evolution for pharmaceuticals and an opportunity for new entrants. The market for the 48 approved CGT products is expected to reach USD9 billion in the next six years.

Deloitte China Life Sciences & Healthcare Consulting Partner Carrie Xiao, together with Life Sciences & Healthcare Consulting Director David Xie, then interpreted China's CGT market trends and investments. They mentioned that China today is becoming a core market for CGT and dominating CRISPR trials. Deloitte also expects medical devices, production technologies and information systems to boom thanks to CGT market growth.

During a panel session, Deloitte Financial Advisory Partner Amy Cao and Qinli Legal Advisory Partner Cody Chen joined the discussion, together with Philip Pfrang, Amit Agarwal, Carrie Xiao and David Xie, sharing insights on Maximizing access to overseas in-licensing for localized development, Successful Commercial/Operational/Financial Due Diligence in biotech, the enormous potential to develop global IP by Chinese enterprises and navigating regulation to accelerate China market entry. They discussed the challenges and opportunities facing CGT industry players, as well as provided suggestions on coping with those challenges to achieve commercial excellence in CGT.

After the seminars, participants expressed high regard for the organization and value of this roadshow. Through this opportunity, we gathered industry experts and clients who focus on CGT together to discuss the future development of this market, facilitating communication and collaboration among industry players.

Did you find this useful?